By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cornerstone Pharmaceuticals, Inc. 

1 Duncan Drive

Cranbury  New Jersey  08512  U.S.A.
Phone: 609-409-7050 Fax: 609-409-6035


SEARCH JOBS


Industry
Pharmaceutical






Company News
Cornerstone Pharmaceuticals, Inc. Presents Phase I Data On CPI-613 In Acute Myeloid Leukemia (AML) And T-Cell Non-Hodgkin's Lymphoma (T-Cell NHL) At American Society of Hematology 2016 12/6/2016 6:48:16 AM
Cornerstone Pharmaceuticals, Inc. Appoints Brian Mullaney, M.D., Ph.D., As Chief Medical Officer 11/29/2016 7:58:12 AM
IDT Corporation Announces Investment In Cornerstone Pharmaceuticals, Inc. 11/10/2016 3:37:53 PM
Cornerstone Pharmaceuticals, Inc. To Present At The LEERINK Partners 5th Annual Global Healthcare Conference On Wednesday, February 10, 2016 2/9/2016 8:02:46 AM
Phase I Trial Data For Cornerstone Pharmaceuticals, Inc.' CPI-613 In Combination With Modified Fluorouracil, Leucovorin, Irinotecan, And Oxaliplatin (mFOLFIRINOX) In Metastatic Pancreatic Adenocarcinoma To Be Presented At The Annual Gastrointestinal Cancers Symposium 1/26/2016 5:58:42 AM
Cornerstone Pharmaceuticals, Inc. Receives Funding Through New Jersey's Technology Business Tax Certificate Transfer Program 1/22/2015 7:30:31 AM
Cornerstone Pharmaceuticals, Inc. Initiates Phase I Clinical Trial Of CPI-613 For The Treatment Of Metastatic Colorectal Cancer 1/12/2015 9:18:51 AM
Cornerstone Pharmaceuticals, Inc. Commences Phase I Clinical Trial Of CPI-613 For The Treatment Of B-Cell Non-Hodgkin Lymphoma 12/8/2014 7:27:30 AM
Cornerstone Pharmaceuticals, Inc.' CPI-613 Selected As One Of Informa And Kantar Health 2014 Top 10 Most Interesting Oncology Projects To Watch 11/13/2014 11:19:05 AM
Cornerstone Pharmaceuticals, Inc. Announces Positive Phase I Data For CPI-613 In Relapsed Or Refractory AML Patients To Be Presented At 2014 American Society of Hematology Annual Meeting 11/6/2014 10:35:31 AM
1234
//-->